Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764472 | 0.84 | ALDH1A1 (0.46) | HSD17B10KDM4EALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL844617 | 0.84 | — | — | |
| SCHEMBL16385554 | 0.82 | KDM4E (0.53) | HSD17B10KDM4EALOX15TSHRSMN1; SMN2 | |
| SCHEMBL20327046 | 0.82 | KDM4E (0.53) | HSD17B10KDM4EALOX15TSHRSMN1; SMN2 | |
| SCHEMBL2328827 | 0.82 | KDM4E (0.64) | HSD17B10KDM4EALOX15TSHRSMN1; SMN2 | |
| SCHEMBL31271162 | 0.80 | GAA (0.41) | HSD17B10KDM4ESMN1; SMN2EGFRALDH1A1 | |
| SCHEMBL20994019 | 0.80 | GAA (0.46) | KDM4ESMN1; SMN2EGFRALDH1A1HTT | |
| SCHEMBL547366 | 0.80 | GLA (0.63) | HSD17B10KDM4ESMN1; SMN2GLALMNA | |
| SCHEMBL21741224 | 0.79 | KDM4E (0.50) | HSD17B10KDM4EALOX15TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11421103 | 0.79 | GLA (0.67) | HSD17B10KDM4ESMN1; SMN2GLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751404-A2 | Balanced charge polymer and hydrophilic contact lens manufactured therefrom | Hydron Limited (GB) | 1997-01-02 | — | — | EP | claimed |
| EP-0751407-A2 | Balanced charge polymer and hydrophilic contact lens manufactured therefrom | Hydron Limited (GB) | 1997-01-02 | — | — | EP | claimed |
| EP-0751405-A2 | Balanced charge polymer and hydrophilic contact lens manufactured therefrom | Hydron Limited (GB) | 1997-01-02 | — | — | EP | claimed |
| US-5391669-A | Lens formed of water swellable crosslinked polymer containing polymer containing cationic-aninoic pair of unsaturated monomers and nonionic monomers | HYDRON LIMITED (GB) | 1995-02-21 | — | — | US | claimed |
| EP-0563299-A4 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | CESKOSLOVENSKA AKADEMIE VED (CS) | 1994-07-20 | — | — | EP | claimed |
| US-5270415-A | Balanced charge polymer and hydrophilic contact lens manufactured therefrom | ALLERGAN INC. (US) | 1993-12-14 | — | — | US | claimed |
| EP-0563299-A1 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | Hydron Limited (GB) | 1993-10-06 | — | — | EP | claimed |
| WO-1992011301-A1 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | ALLERGAN, INC. (US) | 1992-07-09 | — | — | WO | claimed |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | CELLARITY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| EP-0563299-A4 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | CESKOSLOVENSKA AKADEMIE VED (CS) | 1994-07-20 | — | — | EP | disclosed |
| US-5270415-A | Balanced charge polymer and hydrophilic contact lens manufactured therefrom | ALLERGAN INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0563299-A1 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | Hydron Limited (GB) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011301-A1 | BALANCED CHARGE POLYMER AND HYDROPHILIC CONTACT LENS MANUFACTURED THEREFROM | ALLERGAN, INC. (US) | 1992-07-09 | — | — | WO | disclosed |
| US-4099004-A | CATALYSTS FOR ISOCYANURATE FOAMS | TEXACO DEVELOPMENT CORPORATION (US) | 1978-07-04 | — | — | US | disclosed |
| US-4026836-A | AMINOMETHACRYLATE SALT CATALYST, REACTING A POLYETHER OR POLYESTER WITH AN AROMATIC POLYISOCYANURATE | TEXACO DEVELOPMENT CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2353/4885KDM4E 4212/4885ALOX15 1836/4885 |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2353/4885KDM4E 4212/4885ALOX15 1836/4885 |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2578/4885KDM4E 4324/4885ALOX15 2106/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2353/4885KDM4E 4212/4885ALOX15 1836/4885 |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2578/4885KDM4E 4324/4885ALOX15 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.